1. Scrip
  2. >>Business

GSK’s Malaria Vaccine To Be Made By Bharat Biotech For WHO

Move To Improve Access

 
• By Vibha Ravi

GSK is transferring technology for the manufacture of its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower costs for such programs.

Hands holding paper No mosquito, bite for World malaria day with Stop mosquito sign for prevention of virus,dengue, chikungunya, Zika, Mayaro, Malaria, flavi ep
GSK-Bharat Biotech Partnership For Malaria Vaccine A Welcome Move • Source: Shutterstock

GlaxoSmithKline plc is transferring technology for the manufacture of its malaria vaccine antigen to India's Bharat Biotech for supply of the vaccine, RTS,S/AS01E, to the Malaria Vaccine Implementation Programme (MVIP) being piloted in Ghana, Kenya, and Malawi.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.